On June 5^th, 2017 (US time), the annual conference of the American Society of Clinical Oncology (ASCO) announced a Chinese clinical research on CAR-T, which marks a major breakthrough in the treatment of recurrent multiple myeloma.

At the press conference, Wanhong Zhao, associate professor of hematology at the Second Affiliated Hospital of Xi'an Jiaotong University, introduced the new immunotherapeutic study with evident curative effect.

It is reported that among 35 patients with recurrent and refractory multiple myeloma, the earliest initial therapeutic response appeared 10 days after initial injection of CAR-T cells, the objective response rate being 100%. Evident clinical remission (complete remission or very good partial remission) was achieved in 33 patients (94%) and one-year follow-up studies of five of them have shown stable complete remission and absence of tumor cells in bone marrow. During CAR-T therapy, none of the patients had the serious complications affecting the central nervous system.